Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(100.0%)
2Total
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07571824Phase 1Recruiting

A Study to Assess the Bioavailability and Adhesion of Selegiline TDS in Healthy Subjects

Role: lead

NCT07452692Phase 1Not Yet Recruiting

A Study to Assess the Skin Irritation and Sensitization of Selegiline TDS in Healthy Subjects

Role: lead

NCT06607744Completed

Determine the Bioavailability of Selegiline TDS 6mg/24 Hours vs EMSAM in Healthy Subjects

Role: lead

NCT06528665Completed

Determine PK Profiles of Ozanimod and Its' Major Metabolites in Healthy Subjects

Role: lead

All 4 trials loaded